Observed Signal · Sep 24, 2026 · Market Signal · Source: First Analysis · Impact: 4/5
First Analysis acted as the exclusive financial advisor to Phigenics in its majority growth investment from Battery Ventures
First Analysis acted as the exclusive financial advisor to Phigenics, a healthcare-focused end-to-end water risk management platform, in its majority growth investment from Battery Ventures. The partnership is intended to position Phigenics for continued growth through increased investment in new and existing products, as well as expansion into new markets.
Track First Analysis Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Connected Companies & Entities
1 Entity mappedRelated Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
UK startup Pharosyn raises €2.5 million for pharma competitive intelligence platform
London-based Pharosyn, an AI-powered competitive intelligence platform for biopharma, has raised €2.5 million in a funding round led by Moonfire, with participation from Entrepreneurs First, Transpose Platform, and General Advance. The company plans to expand its platform and support wider adoption across pharmaceutical commercial and portfolio strategy teams. Founded in 2025 by Stephen Cowley and Joshua Hampson, Pharosyn monitors clinical, regulatory, and commercial data sources to produce strategic reports tailored to an organisation's pipeline. The funding is part of a broader trend of AI investment in pharma, with EU-Startups reporting approximately €75.3 million across seven comparable rounds this year.
Aeon Acquires Aware Health, Expands Seed Funding
Zurich-based HealthTech startup Aeon has closed a seed extension, bringing total seed funding to over $14 million (€12 million), and acquired core assets of German blood diagnostics platform Aware Health. The round was co-led by Araya Ventures with participation from existing investors including Concentric, GoHub Ventures, Kadmos Capital, N&V Capital, Bigwave Capital, and Calm/Storm Ventures. The acquisition includes Aware Health's technology platform, contracts, laboratory integrations, network of 45+ blood-draw locations, and customer base of nearly 10,000 active users, with data handled under GDPR. Aeon integrates whole-body MRI with recurring blood diagnostics and AI to create a continuous, longitudinal health record for predictive analytics. The company appointed Pablo Tano as AI lead, marking its second acquisition following Holsain, and accelerates European expansion. Financial details were not disclosed.
Anthropic Acquires Coefficient Bio for $400M
Anthropic acquired Coefficient Bio — a roughly eight-month-old startup with fewer than ten employees — for $400 million in stock. Coefficient Bio was founded by Samuel Stanton and Nathan C. Frey, both ex-Genentech computational biology researchers, and had no public product or disclosed revenue. Anthropic intends to fold the team into its Health Care & Life Sciences division (led by Eric Kauderer-Abrams) to accelerate Claude's capabilities in protein design, biomolecule modelling and other biological foundation-model work. The deal follows Anthropic product launches including Claude for Life Sciences (Oct 2025) and Claude for Healthcare (Jan 2026) and sits alongside prior Anthropic acquisitions (Bun, Vercept). Anthropic closed a $30 billion Series G in Feb 2026 valuing the company at ~$380 billion post-money; the Coefficient deal represents a small dilution (~0.1%) at that scale. The acquisition is positioned as a talent- and domain-expertise buy to deepen Claude's role across R&D and drug-discovery workflows.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.